8-KLeadership Changes

Guardant Health, Inc. 8-K Report, Executive Changes (Apr 23, 2019)

Filed April 23, 2019For Securities:GH

Summary

Guardant Health, Inc. announced on April 23, 2019, a strategic addition to its Board of Directors, appointing Dr. Bahija Jallal as an independent director, effective April 17, 2019. This move expands the Board to eight members and brings a wealth of experience from the biopharmaceutical and biotechnology sectors, including her current role as CEO of Immunocore Limited and prior executive positions at AstraZeneca and its subsidiary MedImmune. Dr. Jallal's appointment is particularly noteworthy for her deep expertise in research and development and executive leadership within the life sciences industry. She has also been appointed to key committees, including the audit and nominating and corporate governance committees, signaling her integral role in the company's governance. Her compensation includes standard director fees, a stock option award, and a restricted stock unit award, indicating alignment with shareholder interests through equity participation. This appointment suggests a continued focus on strengthening strategic oversight and leveraging industry expertise to drive Guardant Health's growth and innovation in precision oncology.

Key Highlights

  • 1Appointment of Dr. Bahija Jallal as an independent director to the Board, expanding it to eight members.
  • 2Dr. Jallal brings extensive experience from leadership roles in the biopharmaceutical and biotechnology industries, including CEO of Immunocore and EVP at AstraZeneca.
  • 3Dr. Jallal has been appointed to the Audit Committee and the Nominating and Corporate Governance Committee of the Board.
  • 4Her compensation includes standard director fees, a $215,000 stock option award, and a $215,000 restricted stock unit award, subject to vesting over three years.
  • 5The appointment of Dr. Jallal is expected to enhance the Board's expertise in relevant scientific and operational areas.
  • 6No undisclosed arrangements or transactions requiring disclosure under Regulation S-K are associated with Dr. Jallal's appointment.

Frequently Asked Questions

Dr. Jallal's appointment is significant as it brings substantial executive and scientific leadership experience from the biopharmaceutical and biotechnology sectors to Guardant Health's Board. Her expertise in research, development, and executive management, particularly within companies like Immunocore and AstraZeneca, is expected to provide valuable strategic guidance and oversight as Guardant Health continues to advance its precision oncology solutions.

Dr. Jallal will receive the standard compensation provided to Guardant Health's non-employee directors. This includes a stock option award and a restricted stock unit award, each valued at $215,000 as of the grant date. These equity awards will vest over three years, contingent upon continued service, aligning her interests with those of the company's shareholders.

Dr. Jallal has been appointed to two key committees of the Board: the Audit Committee and the Nominating and Corporate Governance Committee. Her role on these committees will involve contributing to critical oversight functions related to financial reporting, internal controls, and board composition and governance.

Based on the filing, there are no disclosed arrangements or understandings that would impact her selection, nor are there any transactions or relationships with the company that would be considered reportable under Item 404(a) of Regulation S-K. Guardant Health also enters into its standard indemnification agreement with her, which is customary for directors.